Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 10
1998 6
1999 10
2000 11
2001 28
2002 52
2003 95
2004 110
2005 170
2006 180
2007 175
2008 201
2009 190
2010 217
2011 250
2012 229
2013 211
2014 222
2015 209
2016 185
2017 174
2018 179
2019 195
2020 203
2021 214
2022 209
2023 169
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

3,663 results

Results by year

Filters applied: . Clear all
Page 1
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Thompson GR 3rd, et al. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442484 Free article. Clinical Trial.
In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events that occurred in at least 5% of patients in eit …
In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at l …
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, Viani RM, Sandison T, Pappas PG. Thompson GR, et al. Clin Infect Dis. 2021 Dec 6;73(11):e3647-e3655. doi: 10.1093/cid/ciaa1380. Clin Infect Dis. 2021. PMID: 32955088 Free PMC article. Clinical Trial.
STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or invasive candidiasis (IC). ...
STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin …
Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.
Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda L, Croos-Dabrera R, Fredericks C, Thompson GR. Kullberg BJ, et al. Clin Infect Dis. 2019 May 30;68(12):1981-1989. doi: 10.1093/cid/ciy827. Clin Infect Dis. 2019. PMID: 30289478 Clinical Trial.
Successful overall response at EOIVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adjusted difference -10.8, 95% confidence interval -19.9--1.8). ...CONCLUSIONS: This study did not demonstrate non-inferiority of isavuconazole …
Successful overall response at EOIVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adj …
A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi.
Dos Reis TF, de Castro PA, Bastos RW, Pinzan CF, Souza PFN, Ackloo S, Hossain MA, Drewry DH, Alkhazraji S, Ibrahim AS, Jo H, Lightfoot JD, Adams EM, Fuller KK, deGrado WF, Goldman GH. Dos Reis TF, et al. Nat Commun. 2023 Apr 12;14(1):2052. doi: 10.1038/s41467-023-37573-y. Nat Commun. 2023. PMID: 37045836 Free PMC article.
Here, we identify the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) against CAS-sensitive and CAS-resistant isolates of Aspergillus fumigatus, Candida albicans, C. auris, and CAS-intrinsically resistant Cryptococcus neoformans. ...
Here, we identify the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) against CAS-sensitive and …
Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies.
Perrine-Walker F. Perrine-Walker F. Braz J Microbiol. 2022 Sep;53(3):1101-1113. doi: 10.1007/s42770-022-00739-9. Epub 2022 Mar 29. Braz J Microbiol. 2022. PMID: 35352319 Free PMC article. Review.
Caspofungin and other echinocandins have been used for the treatment of human infections by the opportunistic yeast pathogen, Candida albicans. ...It will highlight some of the issues linked to caspofungin resistance or reduced caspofungin sensitivity in vari …
Caspofungin and other echinocandins have been used for the treatment of human infections by the opportunistic yeast pathogen, Candida …
Caspofungin: a review of its characteristics, activity, and use in intensive care units.
Hashemian SM, Farhadi T, Velayati AA. Hashemian SM, et al. Expert Rev Anti Infect Ther. 2020 Dec;18(12):1213-1220. doi: 10.1080/14787210.2020.1794817. Epub 2020 Jul 23. Expert Rev Anti Infect Ther. 2020. PMID: 32662712 Review.
For initial management of (suspected) invasive candidiasis in critically ill patients, usage of an echinocandin, e.g. caspofungin, has been recommended. AREAS COVERED: In this study, characteristics of caspofungin and its use in intensive care unit (ICU) patients ar …
For initial management of (suspected) invasive candidiasis in critically ill patients, usage of an echinocandin, e.g. caspofungin, ha …
Caspofungin-induced beta(1,3)-glucan exposure in Candida albicans is driven by increased chitin levels.
Wagner AS, Lumsdaine SW, Mangrum MM, Reynolds TB. Wagner AS, et al. mBio. 2023 Aug 31;14(4):e0007423. doi: 10.1128/mbio.00074-23. Epub 2023 Jun 28. mBio. 2023. PMID: 37377417 Free PMC article.
Several reports using murine infection models suggest a role for the immune system, and specifically host beta(1,3)-glucan receptors, in mediating the efficacy of echinocandin treatment in vivo. However, the mechanism by which caspofungin-induced unmasking occurs is not we …
Several reports using murine infection models suggest a role for the immune system, and specifically host beta(1,3)-glucan receptors, in med …
The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy.
Su S, Yan H, Min L, Wang H, Chen X, Shi J, Sun S. Su S, et al. Expert Rev Anti Infect Ther. 2022 Feb;20(2):161-178. doi: 10.1080/14787210.2021.1941868. Epub 2021 Jun 28. Expert Rev Anti Infect Ther. 2022. PMID: 34128761 Review.
EXPERT OPINION: Combination therapy is an empirical strategy for treating refractory Candida infections. Caspofungin has been recommended to treat candidaemia. Caspofungin in combination therapy has some applications, while the efficacy of combination therapy in the …
EXPERT OPINION: Combination therapy is an empirical strategy for treating refractory Candida infections. Caspofungin has been recomme …
Human tissue distribution of caspofungin.
Marx J, Reinstadler V, Gasperetti T, Welte R, Oberacher H, Moser P, Joannidis M, Bellmann R. Marx J, et al. Int J Antimicrob Agents. 2022 Apr;59(4):106553. doi: 10.1016/j.ijantimicag.2022.106553. Epub 2022 Feb 14. Int J Antimicrob Agents. 2022. PMID: 35176477 Free article.
Tissue concentrations of caspofungin were determined in nine clinically relevant tissues taken during routine autopsy of 20 patients who had died during caspofungin treatment or within 23 days of cessation. ...Intermediate concentrations were found in pancreas, skel …
Tissue concentrations of caspofungin were determined in nine clinically relevant tissues taken during routine autopsy of 20 patients …
Caspofungin: an overview.
Morrison VA. Morrison VA. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. doi: 10.1586/14787210.3.5.697. Expert Rev Anti Infect Ther. 2005. PMID: 16207161 Review.
One major limitation of this drug is the lack of an oral formulation. Caspofungin may be considered as a component of combination antifungal regimens. Caspofungin represents a significant advance in the care of patients with serious fungal infections....
One major limitation of this drug is the lack of an oral formulation. Caspofungin may be considered as a component of combination ant …
3,663 results